Increased dose of Eylea to extend treatment intervals

A renowned retinal specialist based in the US, Dr Kenneth Fan joins us this webinar to discuss the increased dose of licensed drug Eylea (aflibercept) to treat wet age-related macular degeneration and diabetic macular oedema. Dr Fan will talk more about the trials which have led to the increased 8mg dose, which could extend intervals between injections up to five months for patients.
Eylea 8mg was approved for use by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK earlier this year. Find out more on how this new treatment could reduce the burden of regular injections for patients.

[@maltipoomom2613]

Is this available in US?

[@MacularSociety]

Hi, this treatment is currently available in the US.